Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong-xian Hu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Zhejiang University. Science. B|January 4, 2020
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myelomaHe Huang, Heng-Wei Wu, Yong-Xian Hu
Onkologie|April 15, 2010
Donor-derived solid malignancies after hematopoietic stem cell transplantationYong-xian Hu, Qu Cui, Bin Liang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2011
Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantationYong-Xian Hu, Qu Cui, Bin Liang, et al.
Current Medical Science|July 4, 2021
Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological MalignanciesKe-Jia Hu, Elaine Tan Su Yin, Yong-Xian Hu, et al.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi = Zhonghua Laodong Weisheng Zhiyebing Zazhi = Chinese Journal of Industrial Hygiene and Occupational Diseases|November 14, 2006
[Amifostine in treatment of five patients with myelodysplastic syndrome]Hong-lan Qian, Zhi-jian Shen, Xu-dong Hu, et al.
Journal of Zhejiang University. Science. B|April 12, 2021
Weathering the storm: COVID-19 infection in patients with hematological malignanciesLin-Qin Wang, Elaine Tan Su Yin, Guo-Qing Wei, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|February 19, 2011
[Anti-cD20scFv/CD80/CD28/zeta specific T lymphocytes eradicate primary chronic lymphocytic leukemia cells in vitro]Hong-Lan Qian, Kang Yu, Zhi-Jian Shen, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|December 15, 2010
[Construction of recombinant retroviruses expressing anti-CD20 scFv/CD80 /CD28/zeta gene and expression in Jurkat cell line]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 27, 2007
[Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Leukemia & Lymphoma|June 8, 2013
Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathwaysKang-Ni Wu, Yan-Min Zhao, Ying He, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Zhejiang University. Science. B|January 4, 2020
Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myelomaHe Huang, Heng-Wei Wu, Yong-Xian Hu
Onkologie|April 15, 2010
Donor-derived solid malignancies after hematopoietic stem cell transplantationYong-xian Hu, Qu Cui, Bin Liang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 29, 2011
Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantationYong-Xian Hu, Qu Cui, Bin Liang, et al.
Current Medical Science|July 4, 2021
Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological MalignanciesKe-Jia Hu, Elaine Tan Su Yin, Yong-Xian Hu, et al.
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi = Zhonghua Laodong Weisheng Zhiyebing Zazhi = Chinese Journal of Industrial Hygiene and Occupational Diseases|November 14, 2006
[Amifostine in treatment of five patients with myelodysplastic syndrome]Hong-lan Qian, Zhi-jian Shen, Xu-dong Hu, et al.
Journal of Zhejiang University. Science. B|April 12, 2021
Weathering the storm: COVID-19 infection in patients with hematological malignanciesLin-Qin Wang, Elaine Tan Su Yin, Guo-Qing Wei, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|February 19, 2011
[Anti-cD20scFv/CD80/CD28/zeta specific T lymphocytes eradicate primary chronic lymphocytic leukemia cells in vitro]Hong-Lan Qian, Kang Yu, Zhi-Jian Shen, et al.
Zhongguo Ying Yong Sheng Li Xue Za Zhi = Zhongguo Yingyong Shenglixue Zazhi = Chinese Journal of Applied Physiology|December 15, 2010
[Construction of recombinant retroviruses expressing anti-CD20 scFv/CD80 /CD28/zeta gene and expression in Jurkat cell line]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|July 27, 2007
[Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity]Yong-Xian Hu, Kang Yu, Ying-Xia Tan, et al.
Leukemia & Lymphoma|June 8, 2013
Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathwaysKang-Ni Wu, Yan-Min Zhao, Ying He, et al.
Pageof 2